Forbes December 1, 2025
Since President Trump issued an executive order in May to have the federal government develop “most-favored nation” price targets for prescription drugs and communicate them to pharmaceutical manufacturers, it’s been difficult to evaluate the model due to a lack of details. About the only thing revealed at the time was that the lowest price would be selected among a set of nations with at least 60% of the United States’ gross domestic product per capita. The most-favored nation deals announced this fall between drug makers and the Trump administration added to questions experts and others had with respect to how prices were determined. Moreover, an array of different prices in, for instance, the obesity drug space, augmented the complexity of...
Today's Sponsors
Today's Sponsor